Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.

  • Authors : Karkeet RM; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.; Zekri AN

Subjects: Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/surgery

  • Source: PloS one [PLoS One] 2022 Dec 08; Vol. 17 (12), pp. e0278282. Date of Electronic Publication: 2022 Dec 08 (Print Publication: 2022).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

تفاصيل العنوان

×
  • 1-10 ل  333 نتائج ل ""ROSUVASTATIN""